Korean J Hematol.  2011 Jun;46(2):135-138. 10.5045/kjh.2011.46.2.135.

Variant Burkitt-type translocation (8;22)(q24;q11) in plasma cell myeloma

• Kim H
• Moon HW
• Hur M
• Yun YM
• Park CM
• Lee MH

• KMID: 1782779
• DOI: http://doi.org/10.5045/kjh.2011.46.2.135

Abstract

Variant Burkitt-type translocation, t(8;22)(q24;q11), is very rare in plasma cell myeloma. We report a 51-year-old male patient with plasma cell myeloma, who showed t(8;22) (q24;q11). He suffered from pelvic pain for two months, and showed IgG, lambda type of monoclonal gammopathy (5.14 g/dL; 49.9% of protein). His bone marrow examination showed increased plasma cells (66.9% of all nucleated cells). Plasma cells (74.9% of all nucleated cells) and monoclonal spike (3.38 g/dL; 42.2%) persisted after three cycles of thalidomide and dexamethasone. Cytogenetic analysis showed complex chromosomal abnormalities: 44,XY,-1,t(2;5)(q33;q13),add(8)(q24.1),t(8;22)(q24.1;q11.2),add(10) (p15), der(11)t(1;11)(q21;p11.2),del(12)(p11.2p13),-13,-14,add(14)(q32),der(15)t(1;15)(p2 2;p11.2),-16,add(17)(q11.2),+21,+1-3mar[cp6]/46,XY[19]. To the best of our knowledge, this is the first report on plasma cell myeloma with a variant Burkitt-type t(8;22)(q24;q11) in the Korean patient. A review of 11 such cases in the literature, including the present case, implicated that plasma cell myeloma with t(8;22)(q24;q11) might be related to advanced stage and poor prognosis.

Keyword

Plasma cell myeloma; t(8;22)(q24;q11); Variant; Burkitt

MeSH Terms

Bone Marrow Examination
Cytogenetic Analysis
Dexamethasone
Humans
Immunoglobulin G
Male
Middle Aged
Multiple Myeloma
Paraproteinemias
Pelvic Pain
Plasma
Plasma Cells
Prognosis
Thalidomide
Dexamethasone
Immunoglobulin G
Thalidomide

Figure

• 

  Fig. 1 Bone marrow aspiration smear showing increased plasma cells (Wright-Giemsa stain, ×1,000).

• 

  Fig. 2 Karyogram of follow-up bone marrow cells by Giemsa banding technique. 44,XY,-1,t(2;5) (q33;q13),add(8)(q24.1),t(8;22)(q24.1;q11.2),add(10)(p15),der(11)t(1;11)(q21;p11.2),del(12)(p11.2p13),-13,-14,add(14)(q32),der(15)t(1;15)(p22;p11.2),-16,add(17)(q11.2),+21,+1-3mar[cp6].

Reference

1. Kim SH, Kim JH, Lee DM, et al. Comparison between conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) for patients with multiple myeloma. Korean J Hematol. 2009; 44:14–21.

2. Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 2008. 4th ed. Lyon, France: IARC Press.

3. Lee KH, Lee YK, Park JY, et al. A case report of t(8;22) with additional chromosomal defects in bone marrow involvement of B cell type diffuse large cell lymphoma. Korean J Clin Pathol. 1998; 18:525–528.

4. Yamamoto K, Hamaguchi H, Nagata K, Taniwaki M. A variant Burkitt-type translocation(8;22)(q24;q11) in multiple myeloma. Report of a new case and review of the literature. Cancer Genet Cytogenet. 1998; 104:98–103. PMID: 9666801.

5. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: An international system for human cytogenetic nomenclature (2009). 2009. Basel, Switzerland: Karger.

6. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011; 86:57–65. PMID: 21181954.

7. Lonial S. Presentation and risk stratification--improving prognosis for patients with multiple myeloma. Cancer Treat Rev. 2010; 36(Suppl 2):S12–S17. PMID: 20472183.

8. Solé F, Woessner S, Acín P, et al. Burkitt's type translocation in multiple myeloma. Leuk Res. 1994; 18:671–673. PMID: 7934142.

9. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001; 98:3082–3086. PMID: 11698294.

10. Taniwaki M, Nishida K, Takashima T, et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood. 1994; 84:2283–2290. PMID: 7919347.

11. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995; 82:41–49. PMID: 7627933.

12. Look RM, Lim SW, Schreck RR, et al. Burkitt translocation (8;22)(q24;q11) in a patient with multiple myeloma. Cancer Genet Cytogenet. 1995; 82:100–102. PMID: 7664237.

13. Mugneret F, Sidaner I, Favre B, et al. Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitts-type translocations. Leukemia. 1995; 9:277–281. PMID: 7869764.

14. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer. 1997; 18:84–93. PMID: 9115968.

15. Sugiyama A, Nakabayashi H, Kondo M, Tominaga T, Shinohara K. Multiple myeloma with variant type translocation, t(8;22)(q24;q11.2). Rinsho Ketsueki. 2009; 50:29–33. PMID: 19225226.